Pharma Pipeline, including new molecular entities and major line extensions. The portfolio will change with time as compounds enter from research, progress through to the next phase of development or enter the market place. The high risk nature of the drug development process also means that it is not unusual for some projects to be terminated if they do not meet the criteria for progression and this will be particularly true in the early stages.

IR Agenda

Investor Updates

Presentations & Events

Pharma Pipeline

Figures & Reports

Share Information

Bond Information

Corporate Governance

Annual General Meeting

Company Background

Document Centre

Contacts

Taj Pharmaceuticals Pipelines

Definitions:

This document outlines the Taj pharmaceuticals product development portfolio as of

31-DEC-04

including new molecular entities and major line extensions. The portfolio will change with time as compounds enter from research, progress through to the next phase of development or enter the market place. The high risk nature of the drug development process also means that it is not unusual for some projects to be terminated if they do not meet the criteria for progression and this will be particularly true in the early stages.

Definitions:

Phase 0: Successful lead optimisation compounds will move into what we call phase zero. These are compounds where specific studies for registration have been initiated and preparation is underway for entry into humans.

Phase 1: Phase 1 is defined as the stage of development where safety studies are initiated and the drug first enter humans.

Phase 2: This phase of development represents the first trials of study efficacy of the compound in humans.

Phase 3: This represents the larger clinical trial usually involving a comparision against a standard comparator compound in preparation for the registration of the compound and approval by regulatory authorities.

Humen Structure